SCHEMBL16893373

SCHEMBL16893373

CCN(CC)CCNC(=O)Cc1cc(C(=O)c2ccc(OC)cc2)sc1-c1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
RXFP1 Q9HBX9 1/20 0.52
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP3A4 P08684 1/20 0.46
MAPT P10636 2/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TP53 P04637 1/20 0.40
MDM2 Q00987 1/20 0.40
RAD52 P43351 1/20 0.39
MCHR1 Q99705 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15546231 0.91 MEN1 (0.53) MEN1KMT2ARXFP1MAPTHPGD
SCHEMBL15547238 0.88 MEN1 (0.56) MEN1KMT2ARXFP1MAPTHPGD
SCHEMBL16893486 0.88 MEN1 (0.57) MEN1KMT2ARXFP1MAPTHPGD
SCHEMBL15546901 0.84 MEN1 (0.59) MEN1KMT2ARXFP1MAPTHPGD
SCHEMBL15547138 0.82 MEN1 (0.47) MEN1KMT2ARXFP1CYP2D6MAPT
SCHEMBL16907796 0.82 MEN1 (0.47) MEN1KMT2ARXFP1MAPTLMNA
SCHEMBL16893415 0.81 MEN1 (0.46) MEN1KMT2ARXFP1MAPTLMNA
SCHEMBL16893414 0.81 MEN1 (0.46) MEN1KMT2ARXFP1MAPTLMNA
SCHEMBL15545878 0.81 RXFP1 (0.75) MEN1KMT2ARXFP1MAPTHPGD
SCHEMBL15546196 0.80 MEN1 (0.55) MEN1KMT2ARXFP1MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
US-9777015-B2 Useful thiophene derivatives in the treatment of diabetes METABRAIN RESEARCH (FR) 2017-10-03 US disclosed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP disclosed
EP-2875010-B1 THIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES METABRAIN RES (FR) 2016-08-31 EP disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES METABRAIN RESEARCH (FR) 2015-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197530-A1 USEFUL THIOPHENE DERIVATIVES IN THE TREATMENT OF DIABETES SLC5A2, SLC5A1, TPMT MEN1 4184/4885KMT2A 4602/4885RXFP1 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.